Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a phase 2, double-blind study to assess the efficacy, safety, tolerability, and pharmacokinetics of NBI-827104 when administered once daily for 13 weeks in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS).
Epistemonikos ID: 1c3824b20035aaf306216878a3ce9f16f38f00a1
First added on: May 07, 2024